Laura Panjwani

Articles

Radium-223 May Enhance Immune Response With Sipuleucel-T in mCRPC

April 26th 2016

Jong Chul Park, MD, discusses the potential synergy of radium-223 and sipuleucel-T, which is being investigated in a clinical trial as a potential treatment for patients with metastatic castration-resistant prostate cancer.

Multidisciplinary Treatment a Growing Need in Liver Cancer

April 26th 2016

Michael Choti, MD, explains the impact of advancements in the treatment of patients with liver cancer and how building on them will require all oncology professionals to work as a team.

Neoadjuvant T-DM1/Pertuzumab Combo Boosts pCR in HER2+ Breast Cancer

April 25th 2016

Angela M. DeMichele, MD, explains the significance of the I-SPY 2 data, the advantages of T-DM1 versus standard of care, and what is on the horizon for the use of T-DM1 in HER2-positive disease.

Expert Hopes Immunotherapy Combos Will Deliver Durable Remissions in RCC

April 21st 2016

Robert Figlin, MD, discusses some emerging agents and ongoing trials that could transform the treatment landscape of renal cell carcinoma.

Rare Sarcomas Pose Significant Hurdles, But Foster Collaboration

April 18th 2016

Damon Reed, MD, discusses the challenges associated with treating rare sarcomas, the importance of collaboration, advancements in the field, and the potential for immunotherapy in the disease.

Liquid Biopsy Offers Alternative to Predicting Osimertinib Response in NSCLC

April 16th 2016

Plasma genotyping can, in most cases, identify T790M-positivity in non-small cell lung cancer, which gives patients the option of receiving the targeted therapy osimertinib without the need for a tumor biopsy, according Geoffrey R. Oxnard, MD.

Study Supports Immunotherapy/Radiation Combo in Head and Neck Cancer

April 8th 2016

Jonathan D. Schoenfeld, MD, discusses potential synergy between radiation therapy, given with or without chemotherapy, and immune checkpoint inhibitors in patients with squamous cell carcinoma of the head and neck.

Immunotherapy Combinations Coming to the Forefront in Melanoma

April 7th 2016

PD-1/PD-L1 should be the backbone of melanoma treatment for many patients, says Jason Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine.

Routine Imaging Not Necessary for HPV-Associated Oropharynx Cancer

April 6th 2016

Jessica Frakes, MD, explains findings from a study that examined treatment and follow-up for HPV-associated oropharynx cancer, and how they could impact clinical practice for the follow-up of patients with the disease.

Expert Explains Key Considerations With Immunotherapy in Melanoma

April 5th 2016

Tara C. Mitchell, MD, discusses what oncologists need to know about using immunotherapies in melanomaâ€â€

Jagannath Hails "Exciting" Era in Treating Myeloma

April 5th 2016

Sundar Jagannath, MD, discusses emerging agents in multiple myeloma he is most excited about, sequencing challenges, and the role for personalized medicine in the disease.

FDA Approvals, New Biopsy Techniques Advance Head and Neck Melanoma Care

April 4th 2016

Carol Rossier Bradford, MD, discusses the treatment and surgical outlook for head and neck melanoma, as well as other subtypes of the disease.

PI3K/AKT Pathway Potential Target for Treating Brain Mets in Melanoma

April 4th 2016

Michael Davies, MD, discusses the biggest challenges in treating brain metastases, what is known about the connection to the PI3K/AKT pathway, and what his future plans are for research in this area.

Expert Discusses Evolving Role of Surgery in Kidney Cancer

April 2nd 2016

Alexander Kutikov, MD, discusses the evolving role of surgery in kidney cancer.

The Future of Sarcoma: Nanotechnology, Immunotherapy, and Shark Research

March 29th 2016

H. Thomas Temple, MD, explains where he sees the future of sarcoma going and what diagnostic technologies and therapeutic advancements he is most excited about.

Expert Projects 2016 FDA Approvals of Nivolumab and Pembrolizumab in Head and Neck Cancer

March 28th 2016

Tanguy Seiwert, MD, discusses the impact of the CheckMate-141 trial in head and neck cancer, the importance of establishing an effective biomarker, and the significance a manageable toxicity profile may have on patients with poor performance status.

Mutational Analysis Advances Precision Medicine in Head and Neck Cancer

March 28th 2016

Ezra Cohen, MD, discusses results of a biomarker analysis and the next steps in understanding biomarkers for afatinib in patients with head and neck cancer.

Byrd Says Frontline Ibrutinib Approval Moves CLL Closer to a Cure

March 24th 2016

John Byrd, MD, explains why he believes the ibrutinib approval is practice changing, and how he thinks the agent should be utilized next.

Eribulin Liposarcoma Approval Advances Precision Medicine in Oncology

March 23rd 2016

George Demetri, MD, discusses the impact of the eribulin’s FDA approval, what oncologists can learn from studying liposarcoma, and the challenges that come with treating a rare disease.

Gomella Discusses Radium-223 Impact in mCRPC

March 23rd 2016

Leonard Gomella, MD, discusses the optimal patient population to receive radium-223 for prostate cancer and how oncologists should best use it.

NEXT PAGE
PREVIOUS PAGE